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Glucocorticoids (GCs) are among the most important drugs for acute lymphoblastic leukaemia (ALL), yet despite their clinical
importance, the exact mechanisms involved in GC cytotoxicity and the development of resistance remain uncertain. We examined
the baseline profile of a panel of T-ALL cell lines to determine factors that contribute to GC resistance without prior drug selection.
Transcriptional profiling indicated GC resistance in T-ALL is associated with a proliferative phenotype involving upregulation of
glycolysis, oxidative phosphorylation, cholesterol biosynthesis and glutamate metabolism, increased growth rates and activation of
PI3K/AKT/mTOR and MYC signalling pathways. Importantly, the presence of these transcriptional signatures in primary ALL
specimens significantly predicted patient outcome. We conclude that in lymphocytes the activation of bioenergetic pathways required
for proliferation may suppress the apoptotic potential and offset the metabolic crisis initiated by GC signalling. It is likely that the link
between GC resistance and proliferation in T-ALL has not been fully appreciated to date because such effects would be masked in
the context of current multiagent therapies. The data also provide the first evidence that altered expression of wild-type MLL may
contribute to GC-resistant phenotypes. Our findings warrant the continued development of selective metabolic inhibitors for the
treatment of ALL.
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In children with acute lymphoblastic leukaemia (ALL) cellular
drug sensitivity is a major component of clinical outcome.
Event-free survival for these patients is now greater than 75%
but a significant number continue to relapse and the outlook
for these is dismal (Gaynon, 2005). Around 10 different drugs
are currently used in paediatric ALL-treatment protocols but
among the most important are the glucocorticoids (GCs).
Early response to prednisolone is one of the most informative
prognostic factors for infant, childhood and adult ALL, with
patients that respond well showing significantly better outcome
(Dordelmann et al, 1999). Moreover, GC resistance is a well-
documented feature of relapse (Klumper et al, 1995; Kaspers et al,
2005). Among the paediatric ALL subtypes, infants and those
with T-lineage ALL are particularly resistant to GCs (Pieters
et al, 1998).
Despite the clinical importance of this class of drug, the exact
mechanisms involved in GC cytotoxicity and the development of
resistance remain uncertain (Schmidt et al, 2006; Tissing et al,
2007). Mutations in the GC receptors (GRs) are commonly found
in cell lines that have been selected for GC resistance by extended
exposure to high drug concentrations, but are rarely found in
primary ALL specimens and are not thought to contribute
significantly to GC resistance in patients (Irving et al, 2005;
Tissing et al, 2005). In lymphoid tumours, the ultimate effect of GC
exposure is activation of apoptosis but it is important to remember
that this differs from many other cell types where GCs in fact
promote cell survival and proliferation (Zhang et al, 2007). It has
been hypothesised that the phenomenon of GC cytotoxicity in
lymphoid tissues is related to the repression of essential metabolic
pathways in these cells (Tonko et al, 2001), indicating that there
may be a distinctive metabolic phenotype associated with this
tissue type. Examples of metabolic features that are specific to
leukaemia cells include the unusual dependencies on endogenously
synthesised cholesterol (Madden et al, 1986) and exogenously
supplied asparagine (Richards and Kilberg, 2006), the latter
forming the basis for the successful inclusion of L-asparaginase
as a cornerstone of chemotherapy for ALL.
Over the past 20 years, our laboratory has developed an
authenticated panel of paediatric ALL cell lines that have
been grown in the absence of drug selection (Kees et al, 2003;
Beesley et al, 2006). We have previously demonstrated that these
cultures retain critical features of the primary disease and that
their drug-resistance profile parallels the spectrum of resistance
that has been observed in primary patient specimens, particularly
in regards to dexamethasone (DEX; Kees et al, 2003; Beesley et al,
2006). Here we have performed gene-expression profiling of
T-ALL cell lines within this panel to identify biological pathways
involved in the development of GC resistance, and have examined
their relevance for the prediction of clinical outcome using
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of diagnosis.
MATERIALS AND METHODS
Cell lines
The cell line panel has been previously described (Kees et al, 2003;
Beesley et al, 2006, 2007) and comprised nine T-ALL lines derived
in our own laboratory (PER cell lines), plus six additional
T-ALL cell lines obtained from external sources (HSB2, CEM,
JURKAT, ALL-SIL, MOLT4, DU.528). PER cell lines were derived
from paediatric ALL bone marrow specimens according to the
method previously described (Kees et al, 1987). DNA finger-
printing confirmed the identity of each of the cell lines (Beesley
et al, 2006).
In vitro drug resistance
The sensitivity of the T-ALL cell lines to methylprednisolone
(MPRED) and DEX has been previously published (Beesley et al,
2006) and was measured over 4 days. The IC50 (drug concentra-
tion that inhibits cell growth by 50%) was used as the measure of
drug resistance. For testing of drugs identified by Connectivity
Map (CMAP) analysis (quercetin, resveratrol, LY294002, rapamy-
cin), the neutral red assay was used because antioxidants have
been shown to interfere with the accuracy of the MTT assay (see
Supplementary Methods). For serum starvation experiments, cells
were incubated in normal tissue culture media containing either
10% or 1% fetal calf serum for 7 days before assessing drug
sensitivity as described above.
Gene-expression profiling
Briefly, RNA was extracted from cell lines in exponential growth
phase and hybridised to Affymetrix HG-U133A microarrays
(Affymetrix, Santa Clara, CA, USA) in accordance with our
previously published protocols (Beesley et al, 2005; Hoffmann
et al, 2005; Gottardo et al, 2007). Microarray data were normalised
using robust multiarray analysis (Irizarry et al, 2003) and all
passed quality control criteria for noise, background, absent/
present calls and 30/50 signal ratios for ACTB and GAPDH.
Analysis of drug–gene relationships
T-ALL cell line IC50 scores and gene-expression values were
log2 transformed before performing Gene Set Enrichment
Analysis (GSEA; http://www.broad.mit.edu/gsea) as described
(Subramanian et al, 2005) for MPRED and DEX separately, using
Pearson’s correlation as metric (10000 permutations). Because not
all genes within a given biological pathway are regulated in the
same direction, analyses were performed using absolute correla-
tion values. Gene Set Enrichment Analysis gene set databases (C1,
C2, C3, C4) were downloaded from the GSEA website (GSEA v2.0,
May 2006), whereas the ICHR Curated database was compiled
using published gene lists (see Results section and Supplementary
Table S1).
Connectivity Map analysis
The top 100 positive and top 100 negative probe sets correlating
with MPRED or DEX IC50 values were analysed using the
CMAP software (http://www.broad.mit.edu/cmap). This tool
identifies compounds that elicit transcriptional responses with
similarities to the gene signature under test, and thus with
potential for synergistic activity. Compounds significantly asso-
ciated with GC-resistance signatures were identified using the
CMAP permuted output. Drugs that demonstrated significant
enrichment scores against both DEX and MPRED were tested for
cytotoxicity against ALL cell lines in the presence and absence of
DEX (see above).
Outcome prediction using MPRED gene sets
Gene Set Enrichment Analysis gene sets associated with MPRED
resistance were modelled for their ability to predict clinical
outcome using previously published microarray data from 59 B-
lineage and 17 T-ALL primary paediatric ALL diagnostic bone
marrow specimens (Beesley et al, 2005). For this we used the
leading edge gene subsets from the top 20 gene sets in each
database (C2, C3, C4 and ICHR Curated), that is a total of 80 gene
sets, each of which represents a particular biological feature,
process or pathway associated with in vitro MPRED resistance. For
each of these gene sets, we first determined their equivalent levels
of expression in the diagnostic patient specimens and then
performed principal component analysis (PCA) to reduce the
dimensionality of the data (B-lineage and T-ALL analysed
separately). The first three principal components from each gene
set were then used in logistic regression to generate a binary
classification of predicted outcomes (i.e., relapse or nonrelapse)
for the two patient cohorts. The log-rank statistics produced from
these initial analyses were found to be highly (artificially)
significant in almost all cases, an artefact of data overfitting by
PCA and logistic regression. To control for this, the data were
re-analysed 999 times using random permutations of the patient
outcome labels to generate true (permuted) P-values for each gene
set. Kaplan–Meier analyses to assess differences in relapse-free
survival were generated using permutation testing to generate
P-values for each gene set.
RESULTS
Gene-expression signatures associated with GC resistance
The resistance profile of the 15 T-ALL cell lines to the GCs
DEX and MPRED has been previously described (Beesley et al,
2006). IC50 values across the panel varied by 4–5 orders of
magnitude, with lines demonstrating high (JURKAT, CEM,
MOLT4, DU.528), intermediate (HSB2, ALL-SIL, PER-117,
PER-487, PER-537) and low (PER-427, PER-604, PER-608,
PER-255, PER-550, PER-606) GC resistances, based on IC50 ranges
measured for MPRED of 0.019–500mgml
 1 and for DEX of
0.0014–500mgml
 1 (Beesley et al, 2006). We have documented
that this naturally occurring spectrum of resistance cannot be
explained by mutations in the GR or variations in GRa or GRb
expression levels (Beesley et al, 2008), indicating that defects
downstream of the GR are primarily responsible for GC-resistant
phenotypes in these cell lines.
The resistance profiles of MPRED and DEX across the panel
(IC50 scores) were correlated with gene-expression profiles as
determined by HG-U133A microarray. The top 20 probe sets
positively or negatively correlating with GC resistance are listed
in Table 1 for both drugs, and extended list in Supplementary
Tables S2 and S3. Among the top 20 probe sets there were four
genes common to both drugs, namely MLL, SOX14, NMT2 and
FLJ13769; among the entire chip there were 550 probe sets that
had a significant correlation (Po0.01) vs both drugs (combined
P-value Po0.0001). Of the genes listed in Table 1, we have
previously identified OPHN1 and NF1 as part of a gene signature
that can distinguish diagnosis and relapse specimens from
paediatric T-ALL patients (Beesley et al, 2005). Because increased
GC resistance is one of the hallmarks of relapse in ALL,
this provides encouraging evidence that the GC-resistance
signature derived from this in vitro model is relevant to the
in vivo situation.
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signatures
To interrogate the biological pathways represented by GC-
resistance signatures, we used GSEA (Subramanian et al, 2005).
Gene Set Enrichment Analysis examines ranked lists of genes for
enrichment of biological pathways contained within four different
databases: C1 (genomic loci), C2 (curated Biological pathways), C3
(genes containing cis-regulatory motifs) and C4 (computational
gene networks). To incorporate pathway information specifically
related to the biology of leukaemia, we manually curated an
additional database (ICHR Curated database, Supplementary Table
S1) using information from 40 ALL-related publications that were
not captured by the GSEA databases, and included gene networks
generated using the STRING algorithm (http://string.embl.de) for
63 genes known to be important in the biology of ALL resulting in
512 gene sets (Supplementary Data File 1). The output from this
GSEA is a ranked list of biological gene sets for each database that
are enriched in the MPRED- and DEX-resistance signatures. The
biological pathways identified from this analysis were highly
similar for both GCs, but were typically more robust, that is were
associated with lower false discovery rates (FDRs) and P-values for
MPRED than for DEX (full details in Supplementary Data Files 2
and 3). In view of this, further analysis was focused on the MPRED
signature. A graphical summary of the biological categories most
significantly enriched in the MPRED signature using the C2, C3, C4
and ICHR Curated databases is shown in Figure 1. The top-ranked
gene sets associated with MPRED resistance from the C2 and ICHR
Curated databases can be found in Table 2 (for full details see
Supplementary Data File 2). The predominant pathways associated
with MPRED resistance were those involving cellular respiration
(oxidative phosphorylation, the electron transport chain and
antioxidant defence), metabolic programs (starvation signalling,
responses to rapamycin, glycolysis and gluconeogenesis, choles-
terol biosynthesis, steroid biosynthesis), proliferation and regula-
tion by the gene MYC. As one would expect, several gene sets were
also identified that are involved in the cellular response to GCs or
other drugs. Notably, this includes a previously described gene
signature associated with GC resistance in primary ALL specimens
(Wei et al, 2006) (Table 2, ICHR Curated gene set no. 7). Several
gene sets were identified that are differentially expressed between
early and late relapse in childhood ALL, an observation that
reinforces the link between GC resistance and aggressive disease.
In accordance with the observation that the MLL gene was highly
correlated to both MPRED and DEX resistance (Table 1), several
gene sets were derived from work studying gene-expression
signatures associated with MLL translocations. No significantly
enriched gene sets were identified using the C1 (Positional)
database in this study for MPRED or DEX, indicating that genes
associated with GC resistance were not confined to particular
genomic loci.
In addition to identifying the biological pathways that are
enriched within gene-expression data, the GSEA algorithm
determines which genes from these pathways contribute most
strongly to the observed phenotype. These are referred to as the
‘leading edge’ genes and those found to be associated with MPRED
resistance are listed in Supplementary Data File 4 along with the
correlation of each gene vs MPRED IC50 values in the T-ALL cell
lines. It was noticeable that the pathways identified by GSEA were
predominately upregulated, as evidenced by an overwhelming
majority of genes in each set showing positive correlation of
expression with MPRED IC50. This cannot be attributed to a bias
towards detection of upregulated genes in the microarray data
because upregulated and downregulated genes were equally
associated with GC resistance when correlated individually
(see Table 1 and Supplementary Tables S2 and S3). Thus,
transcriptional activation appears to be a stronger phenotype of
GC resistance in this model than transcriptional repression.
Notable exceptions to this trend were genes that have previously
been shown to be downregulated in GC-resistant ALL specimens
(Wei et al, 2006); in the present study, downregulation of these
genes was also associated with GC resistance (Supplementary
Data File 4).
GC resistance and cell metabolism
One of the most prominent features associated with GC resistance
in T-ALL in the present study involved upregulation of metabolic
pathways. Closer inspection of these data revealed a compelling
pattern of gene regulation associated with these changes (Supple-
Table 1 Top 20 correlating probe sets associated with steroid resistance (IC50 scores) in T-ALL cell lines
Methylprednisolone (MPRED) Dexamethasone (DEX)
Gene Description Probe R
a Gene Description Probe R
a
GPHN Gephyrin 220773_s_at 0.915 SOX14 SRY-related HMG box 14 208574_at 0.884
SOX14 SRY-related HMG box 14 208574_at 0.91 CLTC Clathrin, heavy polypeptide (Hc) 200614_at 0.881
IGJ Immunoglobulin J polypeptide 212592_at 0.905 NMT2 N-myristoyltransferase 2 215743_at  0.867
MLL Mixed-lineage leukaemia 212079_s_at  0.904 DGKA Diacylglycerol kinase, alpha 80kDa 203385_at  0.863
MLL Mixed-lineage leukaemia 212076_at  0.895 MLL Mixed-lineage leukaemia 212076_at  0.859
MLL Mixed-lineage leukaemia 216624_s_at  0.893 POLI Polymerase (DNA directed) I 219317_at  0.858
— Unknown 210491_at  0.889 SLC35B1 Solute carrier family 35, member B1 202433_at 0.857
MIF Macrophage migration inhibitory factor 217871_s_at 0.886 PEX14 Peroxisomal biogenesis factor 14 203503_s_at 0.856
CLK1 CDC-like kinase 1 214683_s_at  0.882 RPN2 Ribophorin II 208689_s_at 0.852
NCOA1 Nuclear receptor coactivator 1 210249_s_at  0.882 MLL Mixed-lineage leukaemia 216624_s_at  0.851
— Unknown 216532_x_at 0.878 — Hypothetical protein LOC283585 213929_at  0.851
NF1 Neurofibromin 1 211914_x_at  0.877 MLL Mixed-lineage leukaemia 212080_at  0.849
EIF5 Eukaryotic translation initiation factor 5 208708_x_at 0.876 NDUFB1 NADH dehydrogenase (ubiquinone) b1 206790_s_at  0.849
NMT2 N-myristoyltransferase 2 215743_at  0.873 RPN2 Ribophorin II 213399_x_at 0.843
TREX2 Three prime repair exonuclease 2 213334_x_at 0.872 PSMC5 Proteasome 26S subunit, ATPase, 5 209503_s_at 0.843
TARBP2 TAR (HIV) RNA-binding protein 203677_s_at 0.872 — Unknown 221155_x_at  0.841
HSPC132 Hypothetical protein HSPC132 218403_at 0.872 FLJ13769 Hypothetical protein FLJ13769 220719_at  0.840
OPHN1 Oligophrenin 1 206323_x_at  0.87 ELK1 Member of ETS oncogene family 217039_x_at 0.839
FLJ13769 Hypothetical protein FLJ13769 220719_at  0.868 MYCBP2 MYC-binding protein 2 201959_s_at  0.836
ADSL Adenylosuccinate lyase 210250_x_at 0.866 HIST1H4A Histone 1, H4a 208046_at  0.835
aPearson’s correlation coefficient.
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smentary Data File 4). In the C2 data set B90% of the leading edge
genes associated with mitochondrial processes were positively
correlated with MPRED IC50, indicating a general upregulation of
mitochondrial metabolism in resistant cells. This included a large
number of genes involved in the electron transport and ATP
synthetase complexes, as well as most of the major enzymes
involved in the citric acid cycle. Likewise, leading edge gene sets
contained almost complete representation of genes driving
glycolysis and cholesterol biosynthesis. Of particular interest,
expression levels of the GLUT1 glucose transporter, ATP citrate
lyase, a critical enzyme in tumours that links glucose metabolism
to lipid synthesis and hexokinase II, responsible for coordinating
metabolic and apoptotic pathways at the mitochondrial membrane
were significantly correlated with GC resistance (Po0.005 vs both
DEX and MPRED for each gene).
Analysis of the small number of genes downregulated in GC-
resistant cells revealed a complementary biological pattern. These
included CROT, CRAT and SLC25A20 (carnitine octanoyltransfer-
ase, carnitine acetyltransferase and carnitine-acylcarnitine trans-
ferase, which are important in the transport of fatty acids for
mitochondrial b-oxidation); PDK3 (pyruvate dehydrogenase
kinase, responsible for inhibition of pyruvate dehydrogenase, the
enzyme that provides the primary link between glycolysis and the
tricarboxylic acid cycle by catalyzing the conversion of pyruvate
into acetyl-CoA); LCAT (lecithin-cholesterol acyltransferase, which
facilitates the export of cholesterol out of the cell); DBT
(dihydrolipoamide branched-chain transacylase, involved in
branched-chain amino-acid catabolism); and GLUL (glutamine
synthetase). These observations are consistent with an alteration
in amino-acid metabolism and the downregulation of fatty acid
b-oxidation. Together with the enrichment of gene sets associated
with cell cycle, transcription, translation, MYC regulation and
proteasomal pathways (Figure 1, and Supplementary Data Files 2
and 3) the signatures are consistent with activation of biosynthetic
and metabolic pathways to support a proliferative phenotype in
resistant cells.
GC resistance is associated with faster growth rate
To confirm the link between GC resistance and proliferation, we
examined cell line doubling times (Beesley et al, 2006) and found a
significant correlation with both MPRED (Spearman’s r  0.86,
Po0.001) and DEX IC50 values (Spearman’s r  0.65, Po0.01), see
Supplementary Figure S1, with the fastest-growing lines being the
most resistant. To assess this relationship further, we used serum
starvation to inhibit the growth of HSB2 cells and measured the
effect on sensitivity to DEX, MPRED and the cell-cycle-dependent
drug cytarabine (ARAC). Serum starvation in 1% vs 10% fetal calf
serum for 7 days inhibited the growth rate of HSB2 cells by 63%
(Figure 2A) and increased resistance to ARAC as expected
(Figure 2B). In contrast, resistance to both DEX and MPRED
significantly decreased following serum starvation (Figure 2B)
GSEA Curated (C2)
GSEA Motifs (C3)
MYC-regulated gene sets
Response to BRCA1 expression
Metabolic programmes
Cellular respiration
Growth/development
MYC related
Unknown motifs
Other
Control of gene expression
Proteasome
Response to steroids
Other transcription factors
Hypoxia response
Steroid/hormone response
1.5 1.6 1.7 1.8 1.9 2.0
Normalised enrichment score
1.2 1.3 1.4 1.5
Normalised enrichment score
GSEA Neighbourhoods (C4)
Apoptosis/DNA damage response
Control of gene expression
Proliferation/cell cycle
1.6 1.7 1.8 1.9 2.0
Antioxidant defence
Proteasome
Normalised enrichment score
ICHR Curated
Other drug response
Neoplastic phenotype
Early vs late relapse
Associated with MLL disease
1.3 1.4 1.5 1.6 1.7 1.8 1.9
Associated with other ALL subtypes
Proliferation/metabolism
Steroid response/resistance
Normalised enrichment score
Figure 1 Functional categories represented by the top GSEA gene sets associated with MPRED resistance in T-ALL cell lines. The top 20 gene sets from
(A) GSEA Curated (B) ICHR Curated (C) GSEA Gene Neighbourhood, and (D) GSEA Motif databases were grouped into biological categories. Bars
indicate the highest normalised enrichment score (NES) achieved for gene sets within each category.
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contributing factor in determining GC sensitivity.
Prognostic relevance of pathways associated with GC
resistance
To investigate whether the gene sets associated with GC resistance
in T-ALL cell lines in vitro might have prognostic relevance for
patients at the time of diagnosis, we examined microarray data
obtained during a previous study of diagnostic childhood ALL
specimens (Beesley et al, 2005). We modelled the expression of the
leading edge MPRED genes (Supplementary Data File 4) in this
patient data set and assessed the ability of each gene set to predict
relapse. Gene sets that significantly predicted relapse in T-ALL
(n¼17) or B-lineage (n¼59) patient specimens are listed in
Supplementary Table S4. Although the gene signatures used in this
analysis were generated using T-ALL cell lines, several gene sets
could predict patient relapse in both B-lineage and T-ALL patient
cohorts, including those involved with cholesterol biosynthesis
(Po0.005, Figure 3A, and Po0.05 Supplementary Table S4,
respectively) those associated with GLUL (Po0.005, Figure 3B,
and Po0.05. Supplementary Table S4, respectively), and those
regulated by MYC (Po0.05 vs both lineages, Figures 3C and D).
Gene signatures previously associated with DEX resistance in
primary ALL specimens (Wei et al, 2006) also significantly
predicted outcome in both cohorts (Po0.05, Figures 3E and F).
This indicates that many of the biological processes contributing
to GC resistance in ALL may be independent of lineage. In
contrast, gene sets involved with oxidative phosphorylation
(Po0.05, Figure 3G) and the cellular response to rapamycin
(Po0.05, Figure 3H) only predicted relapse in the T-ALL cohort
indicating that these pathways may have particular relevance for
GC resistance in this lineage.
Canonical GC-resistance mechanisms in T-ALL cell lines
Aside from abnormalities in the activation or functionality of the
GR, known resistance mechanisms for GCs include defects in
apoptosis (Erlacher et al, 2005) and altered expression of
metabolising enzymes (e.g., 11b-hydroxyglucocorticoid dehydro-
genase) or multidrug-resistance pumps. To directly assess the
contribution of these mechanisms to GC resistance in our T-ALL
cell lines, we correlated the expression of 142 genes curated from
the literature (corresponding to 253 probe sets) involved in
canonical mechanisms of multidrug-resistance, apoptosis and
survival signalling with MPRED and DEX resistance (Supplemen-
tary Table S5). Genes significantly correlated with both MPRED
and DEX resistance included DCK (deoxycytidine kinase; down-
regulated), CYP3A4 (downregulated), CCND1 (Cyclin D1; upregu-
lated) and the multidrug transporter ABCC9 (upregulated). In
contrast to previous work reporting an association between
prednisolone sensitivity and expression of MCL1 or DAPK1 in
ALL patient specimens (Holleman et al, 2005; Wei et al, 2006), we
found no correlation of these genes with GC resistance in T-ALL
cell lines. Neither was there significant correlation with BIM,
PUMA or BCL-2 that have been shown to be key initiators of both
GC and g-irradiation-induced apoptosis (Erlacher et al, 2005).
However, we did find a positive correlation between GC resistance
and the expression of AIF (apoptosis-inducing factor 1), PARP
(poly ADP-ribose polymerase), SMAC (homolog of DIABLO) and
cytochrome c, all of which are key genes in the initiation
of apoptotic signalling. Although initially counter-intuitive that
expression of these critical pro-apoptotic factors might be
associated with increased GC resistance in ALL cell lines, all of
these genes have important functions in normal cellular function.
PARP has multiple biological functions including regulation of
gene expression, cell division, differentiation and DNA repair,
whereas AIF and cytochrome c have important functions in
mitochondrial metabolism and protection from oxidative stress.
Thus, their positive correlation with GC resistance is likely to be
indicative of biological processes other than initiation of apoptosis.
The only anti-apoptotic factor significantly associated with
resistance to both GCs was TRAF2 (TNF receptor-associated
factor 2). In summary, there was no compelling signature at the
level of gene expression of a coordinated deregulation of apoptotic
pathways underpinning in vitro GC resistance.
Table 2 Top 10 gene sets from GSEA database C2 (top) and ICHR Curated (bottom) datasets enriched in the MPRED-resistance signature
GSEA rank C2 Gene set name (C2 dataset) Functional description P-value FDR
a
1 VOXPHOS Oxidative phosphorylation 0.002 0.115
2 BIOSYNTHESIS_OF_STEROIDS Biosynthesis of steroids 0.013 0.108
3 PENG_RAPAMYCIN_DOWN Downregulated in response to Rapamycin starvation in haematopoietic cells 0.003 0.093
4 PENG_GLUTAMINE_DOWN Downregulated in response to glutamine starvation in haematopoietic cells 0.002 0.105
5 BRCA1_OVEREXP_DN Downregulated in response to BRCA1 induction 0.001 0.098
6 CHOLESTEROL_BIOSYNTHESIS Cholesterol biosynthesis pathway 0.038 0.090
7 ELECTRON_TRANSPORT_CHAIN Electron transport chain 0.009 0.086
8 GLYCOLYSIS_AND_GLUCONEOGENESIS Glycolysis and gluconeogenesis pathway 0.001 0.098
9 SCHUMACHER_MYC_P493_TET_UP Upregulated by MYC expression in human B cells 0.015 0.099
10 IDX_TSA_UP_CLUSTER5 Upregulated during fibroblast differentiation induced by insulin,
DEX, isobutylxanthine
0.002 0.100
GSEA rank Gene set name (ICHR- Curated dataset) Functional description P-value FDR
a
1 YOCUM_PROTEINS_IN_MLL_CELL_LINES_VS_CD34 Proteins expressed in MLL-translocated cell lines 0.001 0.030
2 BHOJWANI_EARLY_VS_LATE_PREB_LINREG Genes differentially expressed between ALL early/late relapse 0.004 0.077
3 YEOH_DAV_MLL Genes associated with MLL-patient subtypes 0.007 0.684
4 RHODES_NEOPLASTIC_META Genes associated with the neoplastic phenotype 0.022 0.740
5 STAUNTON_696860 Response to compound NSC696860 in NCI cell lines 0.031 0.601
6 LAMB_DEX_UP Upregulated in DEX-sensitive ALL cells 0.040 0.664
7 WEI_DOWN_IN_DEX_RESISTANCE Downregulated in DEX-resistant ALL cells 0.040 0.569
8 LAMB_COMBINED_PHENOTHIAZINE Upregulated in response to phenothiazine in cell lines 0.008 0.557
9 KIRSCHNER_SCWABE_ALL_EARLY_VS_LATE_
RELAPSE
Genes differentially expressed between early/late ALL relapse 0.029 0.623
10 STAUNTON_668281 Response to compound NSC668281 in NCI cell lines 0.034 0.577
aFDR¼false discovery rate calculated by GSEA.
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Map)
Recently Lamb et al (2006) described a database of drug–gene
response signatures known as the CMAP that can be interrogated
to identify drugs that may have synergistic mechanisms of action.
We used CMAP to analyse the gene signatures associated with
MPRED and DEX resistance in the present study. Table 3 details
the CMAP drugs that scored significantly in the T-ALL GC-
resistance signatures. Rapamycin scored significantly against
both GC signatures, but was particularly impressive vs DEX
(Po0.0001), confirming previous findings (Wei et al, 2006). Of the
other drugs identified by CMAP in Table 3, there were three that
scored significantly against both DEX and MPRED. These were
LY294002 (a PI3K inhibitor), quercetin and resveratrol (both
polyphenol antioxidants).
To assess the potential synergy of these four agents with
GC cytotoxicity, we tested their effect in ALL-SIL cells in the
presence and absence of DEX for 48h. Rapamycin at 50nM had no
cytotoxic effect on its own in ALL-SIL cells but was found to
significantly enhance the cytotoxic effect of 1mM DEX in a dose-
dependent manner (Figure 4A). Previous reports have demon-
strated a synergistic effect of rapamycin on DEX cytotoxicity in T-
ALL cell lines but in a cell-line-specific manner (Wei et al, 2006;
Bornhauser et al, 2007). Sensitisation of the relatively DEX-
resistant CEM-C1 cell line by rapamycin has been confirmed but
the IC50 for these reported CEM variants is quoted as 410mM,
substantially less than our own (spontaneously resistant) CEM line
(4250mM) (Beesley et al, 2006). We therefore examined whether
rapamycin could sensitise even this highly resistant CEM variant to
the effects of DEX (Figure 4B). Although the effect of rapamycin
was much less than with ALL-SIL, combination of 50nM
rapamycin with 500mM DEX did result in a statistically significant
cytotoxic response, whereas DEX alone had no effect at this very
high concentration. The findings confirm previous reports that
rapamycin can sensitise T-ALL cells to the effect of DEX and
demonstrate that this may be possible even in highly GC-resistant
cell types. Rapamycin is an inhibitor of mTOR (the mammalian
target of rapamycin), a key component of the PI3K/AKT/mTOR
signalling pathway. The PI3K inhibitor LY294002 also targets this
pathway and thus might be expected to have similar effects. Similar
to rapamycin, LY294002 had no direct cytotoxic effects on ALL-SIL
cells (Figure 4C) when added on its own but appeared to sensitise
cells to the effects of DEX; however, the strength of this effect
was more variable than for rapamycin and did not reach statistical
significance.
Both quercetin and resveratrol demonstrated dose-dependent
cytotoxicity in ALL-SIL cells in the absence of DEX (Figures 4D
and E). Importantly, combination of either agent with 1mM DEX
resulted in an additive cytotoxic effect. This is the first assessment
of the cytotoxic effects of these compounds in combination with
GCs in ALL and suggests that their inclusion in therapeutic
regimens may have important clinical benefits.
DISCUSSION
The present study provides compelling evidence that cellular
metabolism and proliferation are important aspects of GC
resistance in ALL. It has long been recognised that an alteration
in cellular metabolism is a fundamental phenotype of cancer
(Warburg, 1956) including leukaemia (Boag et al, 2006), but debate
continues as to the exact nature of the changes involved and their
functional significance. The phenomenon was initially described
by Otto Warburg as an enhanced rate of glycolysis to compensate
for the energy deficiency caused by irreversible mitochondrial
damage and loss of oxidative phosphorylation (Warburg, 1956).
For many years this paradigm was indiscriminately applied to all
types of tumours, but it is now known that mitochondrial function
is often intact in cancer cells and that the metabolic phenotype is
tumour specific, see Moreno-Sanchez et al (2007) for comprehen-
sive review. Although the major form of energy production in
many tumours is indeed glycolytic, others predominantly use
oxidative phosphorylation or a combination of these pathways
(Miccheli et al, 2006; Moreno-Sanchez et al, 2007). The compelling
finding from the present study is that in GC-resistant T-ALL cells
there is transcriptional upregulation of both glycolytic and
oxidative phosphorylative pathways, and that these underpin
macromolecule biosynthesis and a proliferative phenotype. It is
well documented that activation of glycolysis has suppressive
effects on apoptotic potential (Rathmell et al, 2003), whereas
oxidative phosphorylation has been shown to exert both pro-
(Tomiyama et al, 2006) and anti-apoptotic influences on the cell
(Zong et al, 2004). Although the relative balance and thus final
influence of these pathways on apoptotic potential cannot be
directly determined from transcriptional data, it is possible that
the proliferative phenotype described here confers resistance to GC
cytotoxicity through the metabolic suppression of apoptotic
potential. This would explain the resistance of T-ALL cell lines
in the apparent absence of changes in the expression of key
apoptotic regulators. Alternatively, a proliferative phenotype in
ALL cells may indirectly confer resistance to GC cytotoxicity by
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Figure 2 Effect of serum starvation on drug sensitivity in HSB2 cells.
Cells were incubated in tissue culture medium containing either 10% or
1% fetal calf serum (FCS) for 7 days before measuring drug sensitivity.
(A) Growth inhibitory effects of serum starvation after 7 days (arbitrary
units, mean±s.e.m., n¼9). (B) Cytotoxic effects of ARAC, DEX and
MPRED (MTT assay, 4-day drug incubation). Data represent the mean
percentage change in IC50 in serum-starved cells (1%) compared to
control (10%) in 4–7 independent experiments.
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soffsetting the cytostatic pressures and metabolic suppression
induced by GC signalling.
The conclusion that faster growing T-ALL cell lines are more GC
resistant is supported by studies demonstrating that proliferating
human peripheral T lymphocytes are more resistant to DEX than
those that are growth arrested (Gilardini Montani et al, 1999;
Lopes et al, 2007), and that the GC sensitivity of CCRF-CEM cells
can be increased by overexpression of the cell-cycle inhibitor
p16
INK4A (Ausserlechner et al, 2001). We also know that relapse
specimens are both more proliferative and more GC resistant than
diagnostic specimens (Klumper et al, 1995; Kaspers et al, 2005),
and our own and other studies have reported increased expression
of cell-cycle genes at relapse in ALL (Beesley et al, 2005;
Bhojwani et al, 2006), particularly in patients that relapse early
(Kirschner-Schwabe et al, 2006). Importantly, the observation
contrasts with the cell-cycle dependency of most other ALL
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Figure 3 Prognostic significance of leading edge gene sets associated with MPRED resistance in T-ALL cell lines. Graphs show relapse-free survival in
primary ALL patient cohorts (T lineage and B lineage as indicated) predicted based on expression of genes associated with MPRED resistance in T-ALL cell
lines. The gene profiles represent the leading edges of the following GSEA gene sets: (A) CHOLESTEROL BIOSYNTHESIS; (B) STRING GLUL TOP100
ASSOCIATIONS (genes associated with glutamine synthetase); (C and D) V$MYC_Q2 (genes regulated by MYC); (E and F) WEI_DOWN_IN_DEX_-
RESISTANCE (genes associated with DEX resistance); (G) VOXPHOS (oxidative phosphorylation); (H) PENG_RAPAMYCIN_DOWN (genes
downregulated in response to rapamycin). Further details of these gene sets can be found in Supplementary Table S4 and Supplementary Data File 4.
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stherapeutics (e.g., cytarabine, vincristine, thiopurines and the
anthracyclines) where increased proliferation enhances cytotoxic
effects. Overall the combined use of these drugs would be expected
to exert the opposite effect to that of GCs, that is to provide a
selective pressure for the emergence of leukemic clones that grow
more slowly. Indeed a recent study concluded that detection of
minimal residual disease after induction therapy in childhood ALL
is associated with underexpression of genes promoting cell
proliferation (Flotho et al, 2007). It is likely that the relationship
between GC resistance and proliferation is not apparent from such
studies because in the context of current multiagent therapy such
effects would be masked. Only at relapse, when GC resistance
emerges as a dominant feature, does a positive association with
proliferation become more apparent.
It should be stressed that the data provided by this study
represent correlations at the level of transcription and cannot
account for post-transcriptional regulation and the kinetics of
complex biochemical networks. In addition the experiments have
been performed in vitro in conditions where availability of
nutrients, particularly glucose and glutamine, are available in
abundance. However, the data are compelling in their consistency
and are complementary with the known metabolic actions of GCs
(see Supplementary Figure S2). Previous reports have indicated an
elevated glycolytic rate in prednisolone-resistant leukaemia cell lines
(Tissing et al, 2007), and the involvement of carbohydrate
metabolism genes in GC response (Tonko et al, 2001; Schmidt
et al, 2006) and GC resistance in primary ALL specimens (Holleman
et al, 2004). In the present study, GC resistance was significantly
correlated with expression of hexokinase II, the rate-limiting
glycolytic enzyme that has recently been associated both with
induction failure in ALL (Winter et al, 2007) and discrimination
between early and late ALL relapse (Bhojwani et al, 2006). Inhibition
of cholesterol synthesis (required in highly proliferative cell types
for the synthesis of cellular membranes) has been shown to be one
of the earliest parameters affected by GCs in ALL cells (Cutts and
Melnykovych, 1987), and is a critical metabolic event given that
lymphocytes appear to be dependent on cholesterol synthesised
endogenously (Madden et al, 1986). Finally, GLUL expression is
induced by GCs (Harmon and Thompson, 1982) and we have
recently reported that reduced expression of this gene is associated
with adverse outcome in B-lineage ALL (Hoffmann et al,2 0 0 8 ) .T h e
importance of glutamine in ALL is highlighted by the fact that a
significant proportion of the clinical efficacy of L-asparaginase, a
cornerstone of therapy for this disease, is actually due to the
glutaminase activity contained within such preparations (Reinert
et al, 2006). The current data suggest that changes to amino-acid
metabolism are not only fundamental to the leukemic phenotype
but may also contribute to GC resistance.
The canonical pathway involved in nutrient sensing and metabolic
control is one that involves PI3K (phosphatidylinositol 3-kinase),
AKT and mTOR. Synergy between the AKT/mTOR pathway and GC
sensitivity has previously been explored based on the finding that
rapamycin responses show a significant relationship to DEX-
resistance signatures in primary specimens from ALL patients (Wei
et al, 2006; Bornhauser et al, 2007). In the present study, we have
identified a similar association between rapamycin and GC resistance
using in vitro data (CMAP analysis) and have confirmed the ability of
this drug to sensitise even highly resistant ALL cell lines. Importantly,
the expression of leading edge genes from the rapamycin-response
signature in T-ALL diagnostic specimens could predict patient
outcome; the same was true of the gene signatures associated with ex
vivo DEX resistance, demonstrating the clinical relevance of this
previously described signature (Wei et al, 2006). The Connectivity
Map analysis also associated the polyphenol antioxidants resveratrol
and quercetin with GC resistance, compounds that have been shown
to inhibit proliferation and induce apoptosis in a variety of cancer cell
types (Mertens-Talcott and Percival, 2005; Zunino and Storms, 2006;
Roman-Gomez et al, 2007). The ability of these agents to enhance GC
cytotoxicity, together with their favourable toxicity profile (they are
abundant in everyday foods), reinforces the case for inclusion of such
compounds in ALL therapeutic trials.
During the course of this investigation, we found an unexpected
correlation between GC resistance and reduced expression of MLL,
a master transcriptional regulator essential for normal mammalian
development and haematopoiesis (Table 1, Figure 1). This
correlation was confirmed to be highly significant vs both MPRED
and DEX by quantitative RT-PCR (data not shown). On the basis of
our data, we hypothesise that the observed correlation with GC
sensitivity in T-ALL cell lines is related to expression levels of wild-
type MLL rather than MLL-translocation products. The relation-
ship between MLL expression, proliferation and GC resistance is
currently being explored in our laboratory.
In summary, the present study provides compelling evidence
that upregulation of cellular metabolism and proliferation is an
important aspect of GC resistance in ALL and may contribute to
patient outcome. We hypothesise that these changes simulta-
neously offset the adverse metabolic consequences of GC signalling
whilst potentially suppressing apoptotic potential through the
modulation of bioenergetic pathways. These observations support
the continued development of selective metabolic inhibitors for the
treatment of ALL, particularly for patients that are likely to be GC
resistant, such as those with MLL rearrangements, induction
Table 3 CMAP drugs significantly associated with MPRED- and DEX-resistance gene signatures in T-ALL cell lines
MPRED DEX
Drug Mechanism of action Enrichment P-value Drug Mechanism of action Enrichment P-value
LY-294002 AKT/PI3K inhibitor  0.507 0.0001 Rapamycin mTOR inhibitor  0.653 o0.0001
Trichostatin A HDAC inhibitor  0.423 0.018 Geldenamycin HSP90 inhibitor 0.655 0.004
Carbamazepine Antiepileptic  0.792 0.020 LY-294002 AKT/PI3K inhibitor  0.397 0.005
W-13 Calmodulin antagonist 0.903 0.021 Sodium phenylbutyrate HDAC inhibitor  0.564 0.014
Blebbistatin Myosin II inhibitor  0.896 0.023 Quercetin ROS scavenger/antioxidant 0.903 0.019
Wortmannin AKT/PI3K inhibitor  0.497 0.024 Resveratrol ROS scavenger/antioxidant  0.630 0.020
Benserazide Amino-acid decarboxylase inhibitor 0.885 0.028 Cobalt chloride Hypoxia mimetic  0.742 0.037
Rapamycin mTOR inhibitor  0.441 0.031 Fludrocortisone Steroid 0.857 0.042
Indomethacin Cyclo-oxygenase inhibitor 0.662 0.031 Deferoxamine Hypoxia mimetic  0.717 0.049
Quercetin ROS scavenger/antioxidant 0.876 0.033
Y-27632 Rho-kinase inhibitor  0.872 0.036
Tamoxifen Oestrogen-receptor blocker 0.740 0.039
Resveratrol ROS scavenger/antioxidant  0.583 0.040
Data indicate the CMAP-calculated enrichment score and permuted P-value for association with GC expression profiles.
T-ALL glucocorticoid resistance
AH Beesley et al
1933
British Journal of Cancer (2009) 100(12), 1926–1936 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sfailure or relapse. Since preparation of this paper, new observa-
tions to support our argument have been published by Hulleman
et al (2009) who reported targeting the glycolytic pathway as a
viable strategy for modulating steroid resistance in ALL.
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